Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

H Lundbeck B (HLUNa)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
28.00 +0.15    +0.54%
10:59:48 - Closed. Currency in DKK ( Disclaimer )
Type:  Equity
Market:  Denmark
ISIN:  DK0061804697 
S/N:  199148222
  • Volume: 42,718
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 27.90 - 28.20
H Lundbeck B 28.00 +0.15 +0.54%

H Lundbeck AS Company Profile

 
Get an in-depth profile of H Lundbeck B, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

5681

Equity Type

ORD

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Contact Information

Address Ottiliavej 9
Valby, 2500
Denmark
Phone 45 36 30 13 11
Fax 45 36 30 19 40

Top Executives

Name Age Since Title
Lars Soren Rasmussen 63 2013 Independent Chairman
Lars Erik Holmqvist 63 2015 Director
Jeremy Max Levin 69 2017 Independent Director
Jeffrey Berkowitz 56 2018 Independent Director
Santiago Arroyo 62 2021 Independent Director
Camilla Gram Andersson 50 2022 Employee Representative Director
Dorte Clausen 38 2022 Employee Representative Director
Hossein Armandi 60 2022 Employee Representative Director
Lasse Skibsbye 39 2022 Employee Representative Director
Lene Skole-Sorensen 63 2015 Deputy Chairman
Dorothea Wenzel 53 2021 Independent Director
Jakob Riis 57 2023 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HLUNb Comments

Write your thoughts about H Lundbeck AS
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mal Vic
Mal Vic Jan 07, 2023 8:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why are financials not available? Please amend.
Jens Peter Zinck
Jens Peter Zinck Jul 21, 2022 12:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Message to https://investing.com: This stock has a wrong name in the header. It is H Lundbeck A (not B)
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email